News Summary

• Dr. Fahar Merchant, President and CEO of Medicenna, will participate in the ROTH 4th Annual Healthcare Opportunities Conference in New York City on October 8-9, 2025.
• Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines.
• Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.
• This format featuring 1-on-1 and small group meetings will offer institutional investors with extensive interaction with executive management to gain in-depth insights into each company.